Get the Stockscreener App
1.29
8.40%
0.10
Gain Therapeutics Inc stock is traded at $1.29, with a volume of 2.75M.
It is up +8.40% in the last 24 hours and down -29.89% over the past month.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
See More
Previous Close:
$1.19
Open:
$1.18
24h Volume:
2.75M
Relative Volume:
3.58
Market Cap:
$56.30M
Revenue:
$55,200
Net Income/Loss:
$-21.24M
P/E Ratio:
-2.192
EPS:
-0.5885
Net Cash Flow:
$-19.37M
1W Performance:
+2.38%
1M Performance:
-29.89%
6M Performance:
-31.75%
1Y Performance:
-34.52%
1-Day Range:
$0.00
$0.00
1-Week Range:
$1.15
$1.33
52-Week Range:
$1.15
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.29 | 56.30M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Gain Therapeutics Stock Price Forecast. Should You Buy GANX? - StockInvest.us
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance UK
Coya Therapeutics, Inc. (COYA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance Singapore
Gain Therapeutics, Inc. (NASDAQ:GANX) Stock Has Average Price Target of $7.50 - MarketBeat
Form 8K Gain Therapeutics Inc For: 1 October By Investing.com - Investing.com India
Form 8K Gain Therapeutics Inc For: 1 October By Investing.com - Investing.com Canada
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders - GlobeNewswire Inc.
Long-term data on a Parkinson’s drug candidate will be presented in Seoul. - Stock Titan
Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com UK
Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com Canada
Gain Therapeutics Inc (NASDAQ: GANX) Share Price, GANX Stock News, GANX Share Price & Updates - kalkine.ca
Xenon Pharmaceuticals Q2 2026 Earnings: Narrower-Than-Expected Loss Supports Modest Stock GainEarnings Quality Analysis - careplusvn.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy - Investing.com
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Gain (GANX) Financial Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; After Results: The Stock Gains 1.97% on the DayEarnings Surprise Stocks - vinanet.vn
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Charm Flow - vinanet.vn
GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX - MarketBeat
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Put Flow Alert - dars.gov.et
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Common Gap - dars.gov.et
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Wyckoff Spring - www.dars.gov.et
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
BTIG Research Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - MarketBeat
Gain Therapeutics, Inc. Q2 2026: Net loss $4.7M, EPS $(0.11) — 10-Q Summary - TradingView
Gain Therapeutics (GANX) faces going-concern risk while advancing Parkinson’s drug - Stock Titan
Gain Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gain Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Gain Therapeutics Q2 Results: EPS Beats Estimates, Loss Narrows - scanx.trade
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall - TradingView
Gain Therapeutics 2Q Loss/Shr 11c >GANX - Moomoo
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update - Yahoo Finance
Gain Therapeutics (GANX) Advances 2% as Support at $1.72 HoldsRetracement Entry - dars.gov.et
Gain Therapeutics (GANX) Advances 2% as Support at $1.72 HoldsWeak Sell Signals - dars.gov.et
Gain Therapeutics Inc (GANX) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - finance.yahoo.com
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
3.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):